MYELOMA HOME PAGE OF SEMMEL-WEIS.ORG

MYELOMA
home page
COV-2019-FACEMASK COVID-2019
home page

COVID-2019
video library

Myeloma Patient Hacking Through
The Big-Pharma Jungle

by Semmel Weis

Click image
Index finger points down at most recent article

  
ODOMZO logo

     DR JOHN NOSEWORTHY:  OUR VISIT TO MAYO (Part 4)
PLEASE PERMIT DR BUADI TO DESCRIBE HIS EXPERIMENT    08 Dec 2018

The question raised in the above discussion remains unanswered to this day: If these millions of dollars of drug shipments are not being used for research as claimed, then what are they being used for? — Semmel Weis

Incongruity arrow

     DR JOHN NOSEWORTHY:  OUR VISIT TO MAYO (Part 3)
IS THE KALAYCIO-BOOM UBIQUITOUS?    12 Nov 2018

If it is reasonable to expect that subjects in clinical trials vanish from the study (mainly by dying or by dropping out) within a year or two of beginning their participation, then the table immediately above should be displaying nothing but zero dollar amounts, simply because none of the subjects originally in the 2007-2009 clinical trial would be available to receive TASIGNA doses in 2013-2017. — Semmel Weis

Dr Matt Kalaycio unable to dispute payment

     DR JOHN NOSEWORTHY:  OUR VISIT TO MAYO (Part 2)
TWO CONTRASTING ATTEMPTS TO MITIGATE CONFLICT-OF-INTEREST EMBARRASSMENT    06 Oct 2018

However, I was surprised to learn that I did receive “Associated Research” payments.  [...]  With appropriate indignation, I explored the Open Payments website to learn more of my hitherto unknown payment.  [...]  The payment was made in January 2017 and our research team cannot verify such a payment was ever received. — Dr Matt Kalaycio

William James Mayo

     DR JOHN NOSEWORTHY:  OUR VISIT TO MAYO (Part 1)
CONFLICT OF INTEREST    12 Sep 2018

I would admonish you, above all other considerations, to be honest. I mean honesty in every conception of the word: let it enter into all the details of your work; in the treatment of your patients and in your association with your brother practitioners. — Dr William James Mayo

Big Pharma bribing politician

  DR PAUL RICHARDSON: WHO CAN A CANCER PATIENT TRUST?   31 Jan 2018

In a first-year pharmacology class at Harvard Medical School, Matt Zerden grew wary as the professor promoted the benefits of cholesterol drugs and seemed to belittle a student who asked about side effects.  Mr. Zerden later discovered something by searching online that he began sharing with his classmates.  The professor was not only a full-time member of the Harvard Medical faculty, but a paid consultant to 10 drug companies, including five makers of cholesterol treatments. — Duff Wilson

Meletios Dimopoulos

  DR PAUL RICHARDSON: DOES THE DISCLOSURE OF EIGHTEEN NUMBERS CLARIFY KAPLAN-MEIER?   25 Jan 2018

Anyone versed in scientific method will recognize that this is grandstanding to an uneducated audience to whom scientific validity is synonymous with testing vast numbers of subjects in far-flung locations, and to which audience the idea would seem fantastic and incredible that testing as few as 10 subjects in a single hospital could possess the full scientific validity that Dimopoulos (2017) with his 929 subjects in 198 hospitals in 27 countries fully lacks. — Semmel Weis

Dr SAGAR LONIAL

  DR PAUL RICHARDSON: DOES PSEUDO-DISCLOSURE LEAD TO MISINFORMED CONSENT?   11 Jan 2018

The drug-company payments involving doctors and hospitals are so large as to more strongly invigorate the hypothesis that the ASCO video shows not at all a discussion between two scientists, but only a drug-company-scripted promo recited by two salesmen. — Semmel Weis

FDA approval process

  DR PAUL RICHARDSON: HOW MANY SUBJECTS PER GROUP?   05 Jan 2018

If it is possible to demonstrate sailors being cured of scurvy using Sailors-Per-Group=2, and if it is possible to demonstrate mice being cured of melanoma using Mice-Per-Group=5, why isn't it possible to demonstrate people being cured of anything at all using People-Per-Group=2 or 5?  And if not 5, then surely 10 would be enough, and if not 10, then surely 15 — but that doesn't begin to approach the FDA requiring sometimes hundreds, and sometimes thousands. — Semmel Weis

Best Hospitals ranking by USNews

  DR PAUL RICHARDSON: DOES A CANCER PATIENT HAVE TO WORRY ABOUT HOSPITAL CORRUPTION AS WELL?   31 Dec 2017

Why does Dana-Farber rake in 39 times the pharma payments of Mayo? What is the essential difference between Dana-Farber and Penn Presbyterian that causes Big Pharma to pay them in the ratio of 992:1? — Semmel Weis

Dr Paul Richardson wearing the recommended badge which reflects that Big Pharma's power over him has the strength of $19.6 million

  DR PAUL RICHARDSON:  WILL YOU WEAR A PHARMA-POWER-DISCLOSURE BADGE?   21 Dec 2017

If a badge or card showing Pharma Power were worn as shown below (much smaller would be fine), conflict of interest disclosure would be delivered not only to the infinitesimally-few people who read footnotes in medical-journal articles, but also to patients receiving therapy, and subjects receiving experimental treatment, and audiences listening to speakers or watching interviews. — Semmel Weis

83% survival at Months=30 is the inflated survival indicated in a misleading Kaplan-Meier graph

  DR PAUL RICHARDSON:  PLEASE JUSTIFY KAPLAN-MEIER   17 Dec 2017

And another reason why you can be expected to be among the very best people in the world to explain Kaplan-Meier is the high trust with which the pharmaceutical industry regards your expertise, as evidenced by its having involved you in payments totalling $19.6 million dollars during Aug2013-Dec2016 for the privilege of tapping into that expertise. — Semmel Weis

Dr ROBERT Z ORLOWSKI, one of the MAGNIFICENT EIGHT represented here as a SUPERMAN in the area of multiple myeloma

  THE MAGNIFICENT EIGHT   13 Dec 2017

It is my belief, a select few myeloma specialists stand above the rest.  These myeloma specialists are innovators, leaders, teachers, patient centric, dedicated, extremely skilled in myeloma treatment, driven, have well above average life expectancies and survival rates, and are just exceptionally caring and kind individuals. — Gary Petersen

FDA Agent Badge gets you into YOU GOTTA TELL THEM THIS

  THE JOHNSON & JOHNSON RAP SHEET — WHO NEEDS TO SEE IT?   21 Nov 2017

Global health care giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and payment of kickbacks to physicians and to the nation's largest long-term care pharmacy provider. — FDA Office of Criminal Investigations

Bright future for Johnson&Johnson DARZALEX

  BRIGHT FUTURE FOR J&J DARZALEX?   24 Oct 2017

As great as sales growth for Imbruvica is, growth for Darzalex is even better.  The multiple myeloma drug is well on its way to blockbuster sales status, with revenue of more than $550 million in the first half of this year, compared with a little over $209 million in the prior-year period. — Keith Speights

Chinese woman holding giant, bamboo-eating rat

  THE 24-COUNTRY-EXPERIMENT     18 Sep 2017

The economic incentives for doctors in poor countries to heed the wishes of the drug companies are immense.  In Russia, a doctor makes two hundred dollars a month, and he is going to make five thousand dollars per Alzheimer’s patient that he signs up. — Donald L Barlett and James B Steele

IS THERE AN ALTERNATIVE TO INFOMERCIALS? THESE FOUR RATS GAVE THEIR LIVES DEMONSTRATING THAT THERE IS AN ALTERNATIVE.

  IS THERE AN ALTERNATIVE TO INFOMERCIALS?    25 Jul 2017

Given that the clinical-trial sponsor — say Johnson&Johnson — can have earlier run the murine-model version at one one-thousandth the cost of the proposed human clinical trial, there can be no excuse for having failed to provide such a murine-model prerequisite to the clinical trial.  To put it another way, patients need to be reassured that they have the right to ask pharmaceutical manufacturers and vendors why they expect humans to play the role of guinea pigs when real guinea pigs have never been asked to play that role. — Semmel Weis

Grim Reaper introduces the SAN MIGUEL (2008) TRILOGY

  THE SAN MIGUEL (2008) TRILOGY   05 Jul 2017

Meanwhile, the suffering patient experiences spontaneous ups and downs, as every patient unexpectedly and inexplicably does, and sooner or later is bound to experience a particularly noteworthy up right after the doctor has performed some dosage tweak, and everybody rejoices in post hoc ergo propter hoc bliss, believing they have witnessed progress in the understanding and control of the disease. — Semmel Weis

Frodo Ring introduces RED BOX WARNING AGAINST KAPLAN-MEIER

  RED BOX WARNING AGAINST KAPLAN-MEIER   04 Jul 2017

The fled/shed patients, then, being out of sight and out of mind of the researchers, may be thought of as patients having become invisible to the researchers, and the impossibility of their ever being recorded on the researchers' data sheets as having died has given them a sort of immortality. — Semmel Weis

Ignaz Semmelweis on Hungarian postage stamp

  IN MEMORY OF IGNAZ SEMMELWEIS     03 Jul 2017

In the mid-19th century, about five women in 1,000 died in deliveries performed by midwives or at home.  Yet when doctors working in the best maternity hospitals in Europe and America performed deliveries, the maternal death rate was often 10 to 20 times greater!  The cause was, invariably, childbed fever.  And a miserable end it was: raging fevers, putrid pus emanating from the birth canal, painful abscesses in the abdomen and chest, and an irreversible descent into an absolute hell of sepsis and death — all within 24 hours of the baby’s birth. — Dr Howard Markel

Semmel Weis in Landeck, Austria with Die Silberspitze (SilverPeak) in the background

  BRIEF BIO   09 Aug 2017

Been there. — Semmel Weis